Cutting-Edge CAR-T Cancer Therapy Is Now Made in India — at One-Tenth the Cost

A small Indian biotechnology company is producing a home-grown version of a cutting-edge cancer treatment known as CAR T-cell therapy that was pioneered in the United States. A single treatment of NexCAR19, manufactured by Mumbai-based ImmunoACT, costs between US$30,000 and $40,000.